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Abstract  
The success of the Regulation on Orphan Medicinal Products in the European Union is evidenced by 
the 127 orphan drugs that have had market authorisation since 2000. However the incentives aimed 
to stimulate research and development have had the unintended consequence of increasing drug 
cost, resulting in many orphan drugs not being cost-effective.  Orphan drugs command an increasing 
share of the pharmaceutical market and account for a disproportionate amount of healthcare 
expenditure.  Orphan drug ownership by socially motivated, not-for-profit organisations may 
facilitate access to more affordable orphan drugs, for the benefit of patients and healthcare systems 
alike. Using repurposed drugs as a paradigm, this review navigates the regulatory hurdles, describes 
the legal context and identifies funding opportunities, in a bid to facilitate and encourage not-for-
profit organisations to lead on the development of affordable orphan drugs. 
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Introduction 
The introduction of the Regulation on Orphan Medicinal Products in the European Union (EU) in 
2000 [1] has been successful in making drugs for rare disorders commercially viable. Incentives 
associated with orphan drug status – principally the 10 years of market exclusivity – have facilitated 
the development of 127 orphan drugs to date. However, there remains considerable unmet need for 
the estimated 27 to 36 million people in the European Union affected by the 5-8000 rare diseases 
[2]. The International Rare Disease Research Consortium has set an ambitious objective to deliver 
200 new therapies for rare disease by the year 2020, and with 1,404 active Orphan Designations 
currently in place, this target may be achievable.   
Despite successes with the development of new medicines for rare diseases, orphan drug 
regulations have had the unintended consequence of high costs [3], allowing orphan drug 
manufacturers to profit excessively from the incentives on offer [4]. A number of orphan drugs are 
not deemed to represent good value for money [5], even with special allowance for exceeding 
conventional thresholds of cost-effectiveness [6].  A 2010 review of access to orphan drugs across 
Europe found that only 21 were widely available, 25 had limited availability and 14 orphan drugs 
were scarcely available [7]. The increasing cost of orphan drugs is a concern at a time when 
European countries face economic difficulties, and budget-constrained health care systems find it 
difficult to meet the escalating demand for treatments. Solutions are needed; not only to promote 
and sustain innovation, but also to ensure that patients with rare diseases can access effective and 
affordable medicines once Marketing Authorisation has been granted.  
We propose a greater role for not-for-profit organisations to become market authorisation holders. 
Ownership of intellectual property (IP) rights by socially motivated organisations may facilitate 
access to more affordable orphan drugs, for the benefit of patients and healthcare systems alike. 
Some of the barriers to ownership of orphan drugs by not-for-profit organisations are likely to result 
from financing, but also from unfamiliarity with the required procedures, uncertainty about the level 
of evidence required, lack of resources for applying for market authorisation and a lack of 
knowledge about the obligations to maintain registration [8]. Moreover, there may be a lack of 
clarity on patent or Intellectual Property issues and potential issues of liability.  
The purpose of this review, therefore, is to provide an overview for public sector and not-for-profit 
organisations, of the processes and procedures for orphan drug designation and regulatory 
approval. The review is structured as follows: (i)  ownership of orphan drugs by not-for-profit 
organisations, with repurposing of drugs for orphan indications as a paradigm; (ii) Cost of 
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repurposed orphan drug development; (iii) Business models for orphan drug development by not-
for-profit organisations; (iv) Intellectual Property issues and opportunities that might arise; and (v) a 
step-by-step guide to the European regulatory process.  
i. Ownership of orphan drugs by not-for-profit organisations 
Public sector and other not-for-profit organisations are as entitled as biotech and pharmaceutical 
industries to be sponsors for orphan designations and become market authorisation holders of 
drugs, including orphans.  
Clinicians and academics are already instrumental to drug development, and are an important 
source of innovative medicines in the European Union [9] but none are yet orphan MA holders.  
Commercial sector dominance in the orphan drug market is illustrated in Table 1, with 93% of 
orphan designations and 100% of products. The number of hospitals or universities that are named 
as sponsors for Orphan Designations in the EuOrphan database is only 26 (out of 1,110), with a 
further 31 sponsored by individuals and 19 sponsored by charities or patient groups.  While many 
sponsors of orphan designations are outside the for-profit commercial sector, none are orphan drug 
market authorisation holders. 
--- Insert Table 1 here --- 
The greatest opportunity for not-for-profit organisations (including universities, health services, 
charities or philanthropic enterprises) to make a significant contribution to bring affordable orphan 
drugs to market is with repurposed (or repositioned) drugs. Kesselheim et al [11] described the roles 
of academia in rare disease drug repurposing in the USA, highlighting that many drugs or drug 
classes approved by the Food and Drug Administration between 1984 and 2009 were based on 
discoveries made by academic researchers who were supported by federal government funding. Far 
fewer medicines had originated solely within pharmaceutical industry research programmes. In fact, 
for-profit commercial sector involvement in repurposed drug development has been restricted by 
the lack of potential returns on investment. This is because the cheap generic drug can easily 
substitute for the branded repurposed medicine if method-of-use patents are difficult to enforce.  
Repurposing off-patent drugs overcomes numerous challenges associated with the research and 
development of new drugs [12]. The opportunities offered are that they have already been well 
characterised in terms of pre-clinical toxicity, ADME (absorption, distribution, metabolism and 
excretion) and safety, as well as having established processes for production. The data requirements 
for licensing a repurposed drug are also less, especially with respect to the demonstration of safety, 
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and developers may utilise an alternative legal basis for a market authorisation, taking existing 
knowledge into account, and requiring fewer pivotal trials to satisfy the requirements of the 
regulatory authorities. Bibliographic evidence is permitted to support market authorisation 
applications [13]. Consequently, repurposed drugs come to market quicker and are more likely to be 
approved than new drugs [14-17]. EMA-approved repurposed (and rediscovered) drugs with orphan 
indications represent just 20% of all orphans, indicating a lost opportunity which industry neglects. 
ii. Cost of repurposed orphan drug development 
While the cost of developing a new drug is very high [18,19], the costs of bringing repurposed drugs 
to market are significantly lower [12], particularly after discounting the cost of discovery [20]. The 
not-for-profit organisation Drugs for Neglected Diseases initiative, for instance, has earned approval 
for six treatments over a period of 10 years, and put another 26 drugs into development, all for 
US$290 million [21].  
Notwithstanding any clinical studies, there are costs involved in applying for patents, product 
manufacture, marketing, promotion, distribution, sales, and supply [22]. But these may be limited: 
the cost of marketing and advertising orphan drugs, especially for the rarest diseases, is 
comparatively small because the target populations of physicians and patients are themselves so 
small [14]. Agreements with for-profit pharmaceutical companies may be necessary for 
manufacture, distribution and supply [23]. This represents a potential threat to achieving the aim of 
low cost medicines and there are numerous recent examples of generic drug ‘price gauging’, where 
cheap products are priced above market rates under conditions of monopoly [24]. However, 
alternative models are available. The not-for-profit pharmaceutical company OneWorldHealth 
(http://oneworldhealth.com/), as one example, is partnering with the International Dispensary 
Association, a not-for-profit drug supplier based in The Netherlands, to manufacture the off-patent 
aminoglycoside antibiotic paromomycin, in India in order to maintain a pricing structure at US$10 
per adult and US$5 per child [23]. 
iii. Business models for orphan drug development by not-for-profit organisations 
A key challenge for non-for-profit development of orphan drugs is in their financing. Despite the 
savings possible through repurposing old drugs, there remain significant costs which may be 
financed in different ways [20].  
Though not repurposed, ivacaftor is the first orphan drug developed through “venture 
philanthropy”—a partnership between a charity and a drug company. This model provides a 
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mechanism for non-profit organisations (in this case, the Cystic Fibrosis Foundation) to help finance 
the development of a treatment in return for a share in profits that can be re-invested in other new 
treatments [25]. The converse is needed for public or other not-for-profit ownership of repurposed 
orphan drugs—that is, a model for the private, public or charitable (including philanthropic) 
financing of drug development by not-for-profit organisations.  
One option is for the public sector to (co-)fund research and development activities, and then own 
or share ownership of the orphan medicinal product. Across Europe, more than €620 million in 
funding was awarded by FP7 to over 120 research projects on rare diseases and orphan medicinal 
products [26]. Horizon 2020 and the Innovative Medicines Initiative have maintained a strong 
commitment to fund research in rare diseases, and represent important funding opportunities, 
which may have wider societal benefits if orphan drugs resulting from these investments are 
ultimately affordable to healthcare systems. Example schemes in the UK include the National 
Institute for Health and Research (NIHR) Invention for Innovation (i4i) and the Health Innovation 
Challenge (HIC) Fund which support translational research to advance interventions for increased 
patient benefit. The NIHR’s Rare Disease Collaboration is supported by a £20m investment and 
includes pharmaceutical industry partners for developing repurposed drugs for orphan diseases.   
Alternative models of financing include Social Impact Bonds, which are arrangements between one 
or more government agencies and an external organisation, where the government specifies an 
outcome and promises to pay the external organisation a pre-agreed sum if it is able to achieve the 
outcome. The UK charity Findacure (http://www.findacure.org.uk/), for example, secures funding for 
phase II clinical trials of generic drugs repurposed for rare diseases that have a high cost of care to 
the NHS. Successful trials lead to off-label prescription in the NHS, and reduce the healthcare cost of 
patients. The NHS then pays a proportion of their savings back to the charity as a success payment. 
The Fair Medicine foundation (http://fairmedicine.eu/) aims to offer sustainable and affordable 
access to medicines in the Netherlands and is centred on partnerships to share responsibilities, risks 
and rewards, and funding from the Ministry of Public Health, Welfare and Sport. 
Other initiatives include Cures Within Reach (http://www.cureswithinreach.org/), which repurposed 
the generic drug sirolimus for autoimmune lymphoproliferative syndrome, and Amadeus Capital 
Partners who are financing the Cambridge start-up company Healx (http://healx.io/) to help 
progress its work in the field of repurposing existing medicines for new rare diseases. 
Capital raised through crowdfunding represents a new approach to financing biomedical research 
and development. In one study, potential donors stated an overwhelming preference for projects 
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conducted by non-profit research organisations and for projects that have the potential to yield a 
curative therapy in paediatric diseases [27]. However, preferences for donation were higher for 
common diseases than for rare diseases.  
iv. Intellectual Property issues and opportunities  
Although not an intrinsic part of the regulatory evaluation process, due thought and consideration 
must be given to the intellectual property aspects of repurposed orphan drug development both to 
understand the existing intellectual property landscape and to determine whether any protection is 
available. This key step involves a search of patent registers to find any existing patents or patent 
applications which cover the drug in question.  
A check for supplementary protection certificates (SPCs) should also be carried out.  Sometimes 
referred to as “patent extensions”, an SPC does not technically extend the life of the patent; instead 
a “new” right is granted which protects an authorised product which is protected by the patent.  An 
SPC is granted to provide an additional period of protection after patent expiry to a patent holder 
who “lost” part of the patent term due to the length of time taken to get regulatory approval and 
get their medicinal product on to the market. SPCs are granted on a national basis.  
Even if the patent covering the compound itself has expired, there may be patents which protect the 
use of the compound for a particular indication or protect a particular route of administration or 
dosage regimen.   
If the proposed orphan drug is to be given a brand name (as opposed to using the trade or generic 
name) then trademark registers should be searched to ensure the brand name is not identical or 
similar to any existing trademarks. 
Finally, it is important to confirm that the original regulatory data exclusivity period for the drug in 
question has expired. In the EU, there is a data protection and market exclusivity period for 
nationally or centrally authorised products. Known as the “8+2+1 formula”, the market authorisation 
holder is granted eight years of data protection (which means that third parties are prevented from 
referring to the registration dossier of the reference medicinal product) followed by a two-year 
period during which a generic product cannot be placed on the market. This period can be extended 
by up to one additional year if an authorisation for a new therapeutic indication is granted.  
An orphan drug is entitled to market exclusivity for a period of 10 years (or 12 years in the case of a 
paediatric orphan disease). This was confirmed in a recent decision of the Court of Justice of the 
European Union [28]. 
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Once the IP landscape has been established, the timeline for development should be considered. 
Ideally, the drug in question will already have become generic and there will be no existing patents 
to consider. Even if patents do remain in force, it is possible to carry out certain types of clinical trials 
using the product as there is a defence to patent infringement in the UK (and most European 
countries) which covers such trials. However, any product which is to be commercialised as a result 
of the trials cannot be marketed until the relevant patents have expired. As clinical trials are 
expensive and time-consuming, carrying them out during the life of an existing patent at least puts 
the orphan drug developer in an advantageous position to commercialise the orphan drug as soon 
after patent expiry as possible. 
With regards to protecting intellectual property in the new indication, the first consideration is 
whether there is any desire on the part of the developer/ market authorisation holder of the orphan 
drug to prevent existing manufacturers of that drug from selling it to treat the new orphan 
indication.  
Existing manufacturers of the drug could apply for a new indication to be included in a second 
market authorisation to cover the new orphan indication should they wish to sell the drug for that 
indication (orphan and non-orphan indications cannot be included in the same market 
authorisation). This would need the orphan holder to consent. If the developer/ market 
authorisation holder of the orphan drug is willing to allow third parties to rely on the data in their 
market authorisation application for the orphan indication and to be free to sell the drug for the 
treatment of the new orphan indication then there is no need to consider seeking patent protection 
(and the developer will not take advantage of the market exclusivity period). Equally, the other 
generic products may be used to treat the orphan indication off-label.  
However, if the developer does want to prevent anyone else selling the drug for the new orphan 
indication then they should consider whether the new indication is one which is a patentable 
invention. In order for something to be patentable, it has to be new and inventive.  It is an often 
misunderstood concept that exploiting old drugs for new uses is not novel drug discovery. However, 
patents can be (and are) granted for so-called second medical uses. This is in recognition of the fact 
that developing new uses for known compounds can involve a great deal of time, effort and research 
and provides significant benefit to society. Patents can also be granted for novel routes of 
administration or novel dosage forms. 
Applying for a patent for the first time can be a daunting process and it is advisable to engage the 
services of a patent attorney both to explain the process and to draft the application.  It is important 
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not to discuss the invention with anyone before a patent application has been filed unless that 
person has signed a confidentiality undertaking. This includes publications and presentations in 
conferences. This is to ensure that the novelty and inventiveness of the idea is preserved until the 
patent has been filed. In Europe, it is possible to file one patent application at the European Patent 
Office and to request that it is validated in all 38 countries in Europe which are members of the 
European Patent Organisation. Alternatively, individual national applications can be made in each 
country where patent protection is desired.  
It can be a relatively expensive process to file a patent application and to prosecute it through to 
grant. As well as patent attorney fees, there will also be filing fees (and if the patent is granted, 
annual renewal fees which increase through the life of the patent). However, filing a patent 
application can be a good way to test the water as the application will be reviewed and analysed by 
the relevant patent office which should identify any issues with the patentability of the ‘new’ 
indication (e.g. it is not novel or inventive because there are prior published documents which 
disclose the same idea). If such issues are raised, a strategic decision can be taken at that stage as to 
whether or not to proceed with the application.  The application will be published around 18 months 
after filing with the European Patents Office and as of that date, the public are on notice that a 
patent application has been filed and on notice of its contents.  
In the case of a patent to a compound itself, the patentee can prevent third parties making, using, 
selling, importing or keeping the compound covered by the patent (often called 'direct 
infringement').  In the case of an orphan product where it is the indication which is protected, the 
analysis is more difficult because there may only be infringement where the compound is sold etc. 
for the protected indication. The scope of such second medical use patents is currently being tested 
in the on-going UK case of Warner Lambert v Actavis where Warner Lambert has a second-medical 
use patent to pregabalin for the treatment of neuropathic pain. 
A granted patent is a valuable asset. The patent holder can exploit the invention exclusively (subject 
to other third party IP) or can licence the patent to third parties in return for a licence fee.  It is 
important that the patent holder monitors the market to ensure that third parties are not infringing 
its rights; otherwise there is little value in holding the patent in the first place. 
If it is intended that the orphan drug will have a brand name then trade mark registrations should be 
filed. Again, this can be done centrally for the EU through EUIPO (the European Union Intellectual 
Property Office) which results in an EU Trade Mark (EUTM) which offers protection throughout the 
 
 
10 
 
EU. As with patents, there is a filing fee and the trademark has to be renewed every ten years for a 
relatively modest fee.  
v. Orphan Drug approval in Europe: step-by-step guide  
The regulatory steps to be undertaken during a drug development programme for an orphan drug in 
Europe are listed in Table 2. Of note is that the regulatory demands of bringing an orphan drug to 
market is managed by the European Medicine Agency (EMA), as a centralised procedure according 
to Regulation (EC) No 726/2004 [29], and not by each Member State National Competent Authority. 
--- Insert Table 2 here --- 
Orphan designation is a free service. The procedure involves submission of an application form and 
scientific description of the condition, the product, its mode of action and data showing a promise of 
efficacy using pre-clinical in vivo and/or preliminary clinical data, prevalence estimates and, where 
there are already authorised medicinal products in the condition in Europe, a case for significant 
benefit. Assessment for orphan designation is made by the Committee on Orphan Medicinal 
Products (COMP) which meets every month. Orphan designation may also be granted on the basis 
that the development of a treatment would not otherwise be commercially viable, irrespective of 
the rarity of the disease.  
The cost of regulatory advice represents a potential barrier, so fee reductions or exemption should 
be considered where possible, as appropriate advice can significantly focus the data requirements 
thereby reducing costs overall.  Once an orphan designation has been granted, the sponsor is eligible 
for total or partial fee exemptions [1]. This includes free pre-authorisation activities such as protocol 
assistance (scientific advice), and greatly reduced fees for products using the centralised procedure 
for market authorisation applications, inspections and post-authorisation activities such as 
variations, annual fees, etc. To be eligible for fee waiver, the applicant must register as a Small 
Medium Enterprise (SME) via the SME office at the EMA. Fee waivers for scientific advice requests 
on medicinal products falling under the scheme for priority medicines (“PRIME”) are also available to 
applicants from the academic sector.  
Protocol assistance is a voluntary procedure to obtain scientific advice on the proposed 
development plan, to gain an understanding about regulatory demands and expectations relating to 
the non-clinical, clinical and quality data, and the standards required for market authorisation.  The 
procedure requires the sponsor to provide a detailed overview of their development plans for the 
Scientific Advice Working Party (SAWP), to review and respond to specific questions. The opinion of 
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the SAWP is not legally binding; however better dialogue with regulators has become a key positive 
factor in facilitating market authorisation. It is crucial that protocol assistance is sought before the 
initiation of any pivotal trials, to ensure that the planned work is in line with regulatory 
requirements.  
The proposed legal basis of the market authorisation, determined from Directive 2001/83/EC [13] 
and Regulation (EC) No 726/2004 [29], should be established during protocol assistance. Articles 10 
(Generic, hybrid or similar biological application) and 10a (Well-established use application) are 
relevant to repurposed drugs. Other regulatory considerations for marketing orphan drugs include 
Exceptional Circumstances, Conditional Approval (Article 14 (8)), Accelerated Access (recital 33 and 
Article 14(9)) and Compassionate Use (Article 83) of Regulation (EC) No 726/2004 [29]. Sponsors 
who repurpose a product for a new indication should consider whether a paediatric investigational 
plan is appropriate, which can add an additional 2 years extension to a product’s 10 years of 
marketing exclusivity. This operates separately from the Orphan Regulation. 
All quality, non-clinical and clinical work must of course comply with Good Manufacturing Practice, 
Good Laboratory Practice and Good Clinical Practice standards. This is mandatory for subsequent 
regulatory audits.  Developers may delegate these responsibilities to other organisations. 
Outsourcing such responsibilities to Clinical Research Organisations and manufacturing  facilities is 
common place even among biotech and small scale pharmaceutical companies. 
Regulatory obligations do not end at the time of market authorisation; these continue throughout a 
drug’s lifetime. This is particularly relevant with respect to drug safety, as stipulated in the 
Pharmacovigilance Regulation (EU No 1235/2010) [30]. 
When a sponsor applies for market authorisation, they will also need to re-submit the orphan 
designation for review and maintenance of the designation. This follows the same criteria as at the 
initial orphan designation; however the sponsor must have some data for their product in the 
condition to support a claim for Significant Benefit if there are other authorized medicinal products 
in Europe, and that the incidence and prevalence of the disease has not changed. This is important - 
as it is at this step that the COMP recommends granting of the market exclusivity.  
Once market authorisation has been granted for an orphan drug there will be additional legal 
requirement to address the pharmacovigilance obligations, and any specific obligations defined by 
the CHMP. Again, this legal responsibility can be outsourced to another organisation that has the 
necessary skills and expertise to address these.  
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Conclusion  
Opportunities for orphan drug development resulting in affordable products lie mainly with 
repurposed drugs. These will invariably be limited to small molecules, and so apply to a sub-set of 
rare conditions; the scope for repurposing biologics (biosimilars in the context of off-patent 
products) has yet to be defined. Funding opportunities to support research and development are  
available from national and international public-sector organisations, via charitable and 
philanthropic donations, and by means of social impact funds or similar such schemes. Although the 
regulatory steps required to obtain a market authorisation for an orphan drug are numerous and 
challenging, these are not insurmountable and can be achieved by not-for-profit organisations 
socially motivated to reduce the costs of orphan drugs to the payers of healthcare.  Market 
authorisation holders may of course contract much of the work to specialized organisations. This is 
the preferred approach of many biotech and small scale pharmaceutical companies, and is the most 
effective option for public sector, not-for-profit and charitable organisations.  
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Table 1: Overview of orphan designation and orphan drug sponsor / market authorisation holder 
according to sector 
Sector Orphan Designation MA Sponsor 
Individuals 31 (2.8%) 0 
Hospital / University 26 (2.3%) 0 
Charity / Patient Group / Not-for-profit 19 (1.7%) 0 
Industry 1,034 (93.1%) 93 (100%) 
Total 1,110 93 
Data obtained from EuOrphan: a database focused on drugs aimed to diagnose, prevent or treat a 
rare disease. The EuOrphan project, as described by Stakišaitis et al [10] received an initial financial 
support by the European Union under IT-Technology project (eTen 510774 2003/C 118/19). 
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Table 2: The regulatory steps required for orphan drug approval  
Procedure Timeline Detail and Fees Optional / 
Obligatory  
Orphan Designation  3-9 months  Sponsor applies for 
orphan designation 
based on incidence / 
prevalence and 
therapeutic need  
This procedure is FREE 
Optional – but 
allows access 
to orphan 
rewards and 
benefit 
Web link: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con
tent_000029.jsp 
Protocol Assistance 2-4 months An opportunity to 
ensure that all the 
planned quality, non-
clinical and clinical work 
is in line with what 
regulators want.  
This procedure is FREE.  
Optional – but 
highly 
recommended  
Web link: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con
tent_000049.jsp&mid=WC0b01ac05800229b9 
Paediatric 
Investigation Plan 
(PIP) 
2-4 months Sponsor must apply for 
a PIP at the end of adult 
Phase I and include all 
the details of planned 
studies to be done in 
children.  
This procedure is FREE. 
Scientific Advice from 
the CHMP is also free on 
Obligatory – 
but waiver 
may be 
applied for  
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paediatric specific issues  
Web link: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con
tent_000023.jsp&mid=WC0b01ac05800240cd  
 
Clinical Trial 
Authorisation (CTA) 
3-5 months 
excluding clock 
stop 
Sponsor must apply for 
a CTA in all the MSs that 
studies will occur. This 
needs to include all 
quality, non-clinical and 
clinical data to date.  
Fee applies 
Obligatory in 
every MS 
before trial 
start 
Web link: https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-
authorisation-in-the-uk  
Marketing 
Authorisation 
Application (MAA) 
15-18 months 
excluding clock 
stop 
Once all the studies are 
completed, a MAA is 
submitted to the EMA 
for evaluation. This must 
be submitted according 
to the electronic 
Common Technical 
Document eCTD 
template requirements.  
Reduced fees apply for 
orphan designation 
applications with SME 
status 
Obligatory for 
MA 
Web link: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_con
tent_000197.jsp&mid=WC0b01ac058002251c  
 
